Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김광현 | * |
dc.date.accessioned | 2018-11-21T16:30:54Z | - |
dc.date.available | 2018-11-21T16:30:54Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 1949-2553 | * |
dc.identifier.other | OAK-21945 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246900 | - |
dc.description.abstract | To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years. © Kim et al. | * |
dc.description.sponsorship | Yonsei University College of Medicine | * |
dc.language | English | * |
dc.publisher | Impact Journals LLC | * |
dc.subject | Area under curve | * |
dc.subject | Carcinoma | * |
dc.subject | Early diagnosis | * |
dc.subject | Renal cell | * |
dc.title | Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 9 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 662 | * |
dc.relation.lastpage | 667 | * |
dc.relation.journaltitle | Oncotarget | * |
dc.identifier.doi | 10.18632/oncotarget.23087 | * |
dc.identifier.wosid | WOS:000419615500053 | * |
dc.identifier.scopusid | 2-s2.0-85040605957 | * |
dc.author.google | Kim K.H. | * |
dc.author.google | Lee H.H. | * |
dc.author.google | Yoon Y.E. | * |
dc.author.google | Na J.C. | * |
dc.author.google | Kim S.Y. | * |
dc.author.google | Cho Y.I. | * |
dc.author.google | Hong S.J. | * |
dc.author.google | Han W.K. | * |
dc.contributor.scopusid | 김광현(57191527009) | * |
dc.date.modifydate | 20240222163024 | * |